Ionis Pharmaceuticals, Inc. (IONS)
Automate Your Wheel Strategy on IONS
With Tiblio's Option Bot, you can configure your own wheel strategy including IONS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IONS
- Rev/Share 4.5197
- Book/Share 2.997
- PB 11.1812
- Debt/Equity 2.9641
- CurrentRatio 9.6644
- ROIC -0.1816
- MktCap 5333418090.0
- FreeCF/Share -3.5857
- PFCF -9.3704
- PE -11.6132
- Debt/Assets 0.5013
- DivYield 0
- ROE -0.9206
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IONS | H.C. Wainwright | -- | Buy | -- | $45 | April 7, 2025 |
| Initiation | IONS | Redburn Atlantic | -- | Neutral | -- | $39 | March 31, 2025 |
News
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Read More
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.
Read More
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to
Read More
Ionis to host 2025 virtual Annual Meeting of Stockholders
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting we.
Read More
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Read More
Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP & Chief Global Product Strategy Officer Beth Hougen - EVP, Finance & CFO Jonathan Birchall - SVP & Chief Commercial Officer Eugene Schneider - EVP, Chief Clinical Development & Operations Officer Conference Call Participants Jay Olson - Oppenheimer Gary Nachman - Raymond James Debjit Chattopadhyay - Guggenheim Jessica Fye - JPMorgan Chi Meng Fong - Bank of America Merrill Lynch Yaron Werber - TD Cowen David …
Read More
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.
Read More
Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG - a "blockbuster" indication. Management believes >$3bn revenues and >$2bn royalties + milestones may be achieveable long-term, with multiple new product launches for wholly-owned and partnered assets.
Read More
Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Read More
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over 40 RNA-targeted therapeutics, making it a compelling watch-list candidate.
Read More
Ionis Pharma Beats Expectations for Q4
Published: February 19, 2025 by: The Motley Fool
Sentiment: Positive
Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million.
Read More
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About Ionis Pharmaceuticals, Inc. (IONS)
- IPO Date 1991-05-17
- Website https://www.ionispharma.com
- Industry Biotechnology
- CEO Dr. Brett P. Monia Ph.D.
- Employees 1069